Skip to main content
S 377 116th Congress Senate Health Competition and antitrust Drug safety, medical device, and laboratory regulation Health care costs and insurance Inflation and prices Licensing and registrations Manufacturing Medicare Prescription drugs Product safety and quality Public contracts and procurement

Medicare Negotiation and Competitive Licensing Act of 2019

Introduced: February 7, 2019 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 7, 2019
Read twice and referred to the Committee on Finance.
Feb 7, 2019
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medicare Negotiation and Competitive Licensing Act of 2019

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)

The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.

Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

What's happening now February 7, 2019

Read twice and referred to the Committee on Finance.

 Related & companion bills 1
  • HR 1046 Related bill Medicare Negotiation and Competitive Licensing Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Democratic 3
D
Warren, Elizabeth
Massachusetts · Oct 31, 2019
 D
Baldwin, Tammy
Wisconsin · Feb 7, 2019
 D
Klobuchar, Amy
Minnesota · Feb 7, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). S. 377: Medicare Negotiation and Competitive Licensing Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-S-377/
MLA
"S. 377: Medicare Negotiation and Competitive Licensing Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-377/.
Bluebook (legal)
S. 377, 116th Cong. (2026), https://openamerica.io/bill/116-S-377/.
Markdown link
[S. 377: Medicare Negotiation and Competitive Licensing Act of 2019](https://openamerica.io/bill/116-S-377/)
Report a problem